Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant

Peter Riddell1†, Ram Vasudevan-Nampoothiri2†, Jin Ma3, Lianne G. Singer1, Jeff H. Lipton2 and Stephen C. Juvet1*

Abstract

Background: Late onset non-infectious pulmonary complications (LONIPCs) following allogenic hematopoietic stem cell transplantation (allo-HSCT) confer a significant mortality risk. Lung transplantation (LTx) has the potential to provide survival benefit but the impact of prior allo-HSCT on post-LTx outcomes is not well studied.

Methods: This retrospective, single-centre cohort study assessed the post-LTx outcomes of adults with LONIPCs of allo-HSCT. Outcomes of LTx for LONIPCs were compared to propensity-score matched LTx controls (n = 38, non-HSCT) and recipients of re-LTx (n = 70) for chronic lung allograft dysfunction (CLAD).

Results: Nineteen patients underwent DLTx for LONIPCs of allo-HSCT between 2003 and 2019. Post-LTx survival was 50% at 5-years. Survival to 1-year post-LTx was similar to matched controls (p = 0.473). Survival, conditional on 1-year survival, was lower in the allo-HSCT cohort (p = 0.034). An increased risk of death due to infection was identified in the allo-HSCT cohort compared to matched controls (p = 0.003). Compared to re-LTx recipients, the allo-HSCT cohort had superior survival to 1-year post-LTx (p = 0.034) but conditional 1-year survival was similar (p = 0.145).

Conclusion: This study identifies an increased risk of post-LTx mortality in recipients with previous allo-HSCT, associated with infection. It supports the hypothesis that allo-HSCT LTx recipients are relatively more immunosuppressed than patients undergoing LTx for other indications. Optimisation of post-LTx immunosuppressive and antimicrobial strategies to account for this finding should be considered.

Keywords: Allogenic hematopoietic stem cell transplantation, Lung transplantation, Infection

Introduction

Late onset non-infectious pulmonary complications (LONIPCs) allogenic haematopoietic stem cell transplantation (allo-HSCT) are a significant cause of morbidity and mortality [1]. These complications cover a wide spectrum of respiratory disease, but most commonly present as bronchiolitis obliterans or interstitial lung disease [2]—the aetiology of which is thought to include chronic graft-versus-host-disease (GVHD), toxicity of HSCT conditioning regimens and infection [3, 4].

The management of LONIPCs depends on diagnosis, and response to treatment is variable. Chronic pulmonary GVHD is often managed with immunosuppression,
inhaled corticosteroids, and macrolide antibiotics. However, treatment response is frequently poor [5] and 5-year survival from diagnosis is often less than 50% [6, 7]. For other LONIPCs, such as pleuro-parenchymal fibroelastosis (PPFE) no effective medical therapy is known and progressive disease is common [8].

Lung transplantation (LTx) has the potential to provide both survival and quality of life benefits to patients who develop LONIPCs following allo-HSCT. However, as this is a rare indication for LTx, comprehensive evaluation of post-LTx outcome is lacking. Recipient co-morbidity associated with previous allo-HSCT is likely to impact the post-LTx risk profile, and the clarification of this risk is important to optimise both recipient selection and post-LTx management.

In this study, we describe our institutional experience of LTx for LONIPC of allo-HSCT. We compare post-LTx outcomes to propensity-score matched LTx controls and to recipients of re-LTx for chronic lung allograft dysfunction (CLAD). Our aim in selecting these control groups was to assess whether the presence of a prior allo-HSCT increases recipient risk relative to different LTx populations.

Patients and methods
We retrospectively assessed the long-term outcomes of adults who underwent LTx for LONIPC of allo-HSCT. The study design was a matched-cohort study, with propensity-score matching performed to identify a non-HSCT LTx control group (2:1; n = 38). Patient demographics and post-transplant outcomes were obtained from the Toronto Lung Transplant database and confirmed by electronic healthcare records. The date of data censure was 31st December 2019.

Inclusion and exclusion criteria
This study included adults who underwent double lung transplantation (DLTx) at the Toronto General Hospital between Jan 2003 and Dec 2019. Cystic fibrosis patients colonised with *Burkholderia cenocepacia* were excluded from the propensity-score matching process, as this pathogen has been associated with markedly impaired post-LTx survival [9]. Patients who underwent LTx following non-allogenic HSCT were also excluded. This study was performed with approval of the institutional review board at the University Health Network, Toronto.

Post lung transplant immunosuppression
Induction immunosuppression was not routinely administered. Basiliximab IV 20 mg (day 0 and day 4) was administered if the initiation of calcineurin inhibitor was delayed. All patients received methylprednisolone IV 500 mg at the time of surgery, followed by 0.5 mg/kg 12 hourly for 3 doses. Maintenance immunosuppression included cyclosporine bid (based on trough levels), azathioprine 1.5-2 mg/kg od and prednisone 0.25 mg/kg od (tapering to 0.15 mg/kg over 3 months). Mycophenolate (Myfortic 720 mg bid or Cellcept 1 g bid) was substituted for azathioprine if the HLA screen was cPRA positive. Immunological risk at the time of lung transplant was classified as either standard or high risk, based on virtual or flow antibody cross match (CXM) results. Peri-operative antibody desensitisation was performed for patients with high immunological risk. This included 5 cycles of plasmapheresis, 1 g/kg immunoglobulin and anti-thymocyte globulin (ATG; 3 mg/kg if virtual CXM positive alone, or 5 mg/kg if flow CXM positive) [10]. Post-LTx immunosuppression strategy did not differ in patients undergoing LTx for cGVHD compared to this standard approach.

CMV monitoring, prophylaxis, and treatment
CMV prophylaxis, ganciclovir 5 mg/kg IV od, was commenced at the time of lung transplant. This was changed to valganciclovir 900 mg od once enteral medication could be tolerated. CMV prophylaxis continued for 9 months in CMV IgG donor positive/recipient negative cases (CMV D+/R−), 6 months in CMV IgG D+/R+ cases, and 6 months in CMV IgG D−/R+ cases. CMV IgG D−/R− cases did not receive CMV prophylaxis. Following the discontinuation of prophylaxis, serum CMV PCR was monitored weekly for 3 months. If valganciclovir or ganciclovir was withheld during the planned period of prophylaxis, serum CMV PCR was monitored weekly until recommenced. Further CMV PCR testing was performed as per clinical indication.

In the setting of CMV viraemia, asymptomatic patients were managed with valganciclovir 900 mg bid as an out-patient. The CMV PCR thresholds for treatment of
asymptomatic patients were $\geq 500$ IU/ml (CMV D+/R−) and $\geq 1000$ IU/ml (CMV D+/R+ and CMV D−/R+). Symptomatic CMV infection was treated with IV ganciclovir 5 mg/kg od for a minimum of 2 weeks, or until CMV PCR was down trending and symptoms improving. At this time, ganciclovir was switched to valganciclovir 900 mg bid. Serum CMV PCR was monitored weekly, and treatment discontinued once two negative CMV PCR readings were achieved.

Statistical analysis
The selection of a control group for this retrospective study was performed with propensity score matching, using the optimal match method [12]. The optimal match method produces matches that attain the smallest average propensity score distances across all matched pairs by utilising network flow optimization. The variables included in propensity score matching included recipient age, waiting list status at LTx admission (Additional file 1: Table S2), donor type (donation after cardiac or brain death), donor-recipient gender match, donor-recipient CMV match, immunosuppressive risk profile and follow-up time from LTx.

Data in the results section are expressed as mean (± standard deviation), median (interquartile range) or percentage. Continuous variables were compared using unpaired t-tests. Nominal variables were compared using Fisher’s exact test. Post-transplant survival, time to CLAD and freedom from de novo DSA (donor specific antibody) were estimated by Kaplan–Meier analysis. Hazard ratios for survival were assessed using the Mantel–Haenszel method. Cause-specific hazard ratios for risk of infection was performed using the Andersen-Grill model. The generalized estimating equations model, with an exchangeable correlation structure, was used to assess the association between allo-HSCT and severe CMV infections. Assessment of cumulative incidence functions for competing risk events were performed using Gray’s K-sample test. Statistical analysis was performed using GraphPad Prism Version 8.4.3 and R version 3.6.0.

Results
Patient characteristics
During the study period, nineteen patients underwent DLTx for LONIPCs of allo-HSCT. Chronic myeloid leukaemia (CML; n = 6) was the most common indication for allo-HSCT. 84.2% of patients received matched-related stem cell donations (Table 1). At the time of LTx referral, all patients had developed chronic GVHD affecting at least 1 organ site. Extra-pulmonary chronic GVHD was present in 15 patients, with skin being the most affected site (63.2%, n = 12). Extra-pulmonary GVHD was adequately controlled in all patients prior to LTx, with prednisone (100%; n = 19) and mycophenolate (52.6%; n = 10) being the most prescribed medications.

The median time from HSCT to LTx was 10.2 [2.9–14.4 years] and the median LTx waiting list time was 2.1 [1.0–4.9] months. Explant pathology identified bronchiolitis obliterans in 15 of the allo-HSCT cohort (78.9%). In the propensity-score matched cohort, cystic fibrosis was the most common indication for LTx (60.5%, n = 23), followed by interstitial lung disease (28.9%, n = 11). Four patients in the allo-HSCT cohort (no patients in matched cohort) were receiving immunoglobulin replacement for hypogammaglobulinemia (IgG deficiency) prior to LTx (p = 0.007). Three of the allo-HSCT cohort were also IgA deficient prior to LTx, 1 of which was receiving immunoglobulin replacement therapy for co-existing IgG deficiency. There were no statistically significant differences in recipient age, waiting list time or priority [13], immunosuppressive risk, donor-recipient CMV

### Table 1 Recipient characteristics at the time of allogeneic hematopoietic stem cell transplantation

| Characteristic                              | Allogenic HSCT Recipients (n = 19) |
|---------------------------------------------|-----------------------------------|
| Age at HSCT, years                          | Median [IQR] 31.3 (17.1–38.7)     |
| Sex, % male                                 | 47.40%                            |
| Indication for HSCT                         |                                   |
| CML                                         | 31.6% (6)                         |
| ALL                                         | 21.1% (4)                         |
| AML                                         | 15.8% (3)                         |
| Other                                       | 31.6% (6)                         |
| Stem cell donors                            |                                   |
| Matched related                             | 84.2% (16)                        |
| Matched unrelated                           | 10.5% (2)                         |
| Haplo-identical                             | 5.3% (1)                          |
| Myeloablative conditioning1                 |                                   |
| TBI conditioning                             | 73.3% (11)                        |
| Non-TBI conditioning                         | 26.7% (4)                         |
| Presence of extra-pulmonary GVHD            |                                   |
| Skin                                        | 63.2% (12)                        |
| Eyes                                        | 47.4% (9)                         |
| Oral                                        | 47.4% (9)                         |
| Liver or GI tract                           | 21.1% (4)                         |
| Time from HSCT to LTx                       | Median [IQR] 10.2 [2.9–14.4]      |
| Lung explant pathological diagnosis         |                                   |
| Bronchiolitis obliterans                    | 78.9% (15)                        |
| Pleuro-parenchymal fibro-elasticosis         | 21.1% (4)                         |

1 Conditioning regimen not known for four patients
status, or the proportion of patients bridged to LTx between the LTx cohorts (Table 2). Donor age, type, requirement for ex vivo lung perfusion (EVLP) assessment and ischaemic times were also similar between these cohorts (Additional file 1: Table S3). There was no statistically significant difference in the incidence of post-LTx infections based on pre-LTx GVHD treatment (p = 0.810).

| Table 2 Recipient characteristics at the time of lung transplantation |
|-------------------------------------------------------------|-----------------|-----------------|
| | Allo-HSCT cohort (n = 19) | Matched controls (n = 38) | p value |
| Age, years | Median [IQR] | 39.2 [29.6–48.7] | 35.3 [25.9–54.3] | 0.906 |
| Sex, % male | 47.40% | 63.20% | 0.273 |
| BMI | 19.7 ± 3.2 | 22.0 ± 4.9 | 0.07 |
| Time on waiting list, months | Median [IQR] | 2.1 [1.0–4.9] | 1.8 [0.8–6.2] | 0.488 |
| Indication for LTx | | | |
| | | LONIPCs of allo-HSCT—100% | CF—60.5% (23) | N/A |
| | | ILD—28.9% (11) | PAH—5.3% (2) | |
| | | COPD—5.3% (2) | |
| Waiting listing priority | | | |
| Status 1 | 21.1% (4) | 13.2% (5) | 0.463 |
| Status 2 | 42.1% (8) | 57.9% (22) | 0.279 |
| Status 3 | 36.8% (7) | 29.0% (11) | 0.56 |
| Mechanical or ECLS bridging to LTx | 26.3% (5) | 10.5% (4) | 0.143 |
| Double lung transplant | 100% | 100% | 1 |
| Donor-recipient crossmatch | | | |
| Standard IS risk | 89.5% (17) | 94.7% (36) | 0.855 |
| Increased IS risk | 10.5% (2) | 5.3% (2) | |
| CMV status | | | |
| D−ve/R−ve | 36.8% (7) | 31.6% (12) | 0.769 |
| D−ve/R+ve | 31.6% (6) | 34.2% (13) | > 0.99 |
| D+ve/R−ve | 15.8% (3) | 21.1% (8) | 0.735 |
| D+ve/R+ve | 15.8% (3) | 13.2% (5) | > 0.99 |
| Hypogammaglobulinemia | | | |
| Pre LTx IgG level, g/L | 11.2 ± 4.9 | Not assessed | N/A |
| Pre LTx IVIg replacement | 21.1% (4) | 0% | 0.007 |
| Recipient co-morbidities | | | |
| Ex-smoker | 26.3% (5) | 26.3% (10) | > 0.99 |
| Diabetes | 21.1% (4) | 29.0% (11) | 0.751 |
| GERD | 10.5% (2) | 34.5% (20) | 0.077 |
| Hypertension | 15.8% (3) | 13.2% (5) | > 0.99 |
| Pre-LTx respiratory pathogen history | | | |
| Aspergillus | 42.1% (8) | 34.2% (13) | 0.575 |
| Pseudomonas | 31.6% (6) | 50% (19) | 0.26 |
| NTM | 26.3% (5) | 7.9% (3) | 0.102 |
| Burkholderia | 0% (0) | 7.9% (3) | 0.544 |
| Recipient BAL at LTx | | | |
| Category 1 pathogens | 26.3% (5) | 36.8% (14) | 0.555 |
| Category 2 pathogens | 5.3% (1) | 18.4% (7) | 0.247 |
| Category 1 or 2 | 31.6% (6) | 39.5% (15) | 0.772 |

1 High IS risk is defined as a positive virtual or flow crossmatch at the time of transplant (and received antibody desensitisation at the time of transplant)

2 Presence of <i>Burkholderia cepacia</i> species, but not <i>Burkholderia cenocepacia</i>
Early post-transplant outcomes
Recipients of LTx from the allo-HSCT cohort spent 4.0 [2.0–25.5] days in ICU compared to the 3.3 [2.0–5.3] days of the control group (p = 0.298). The overall post-LTx hospital length of stay (LOS) for allo-HSCT cohort was 23.1 [17.0–101.0] days, compared to 17.0 [13.8–26.0] days in the control cohort (p = 0.009; Table 3). Survival to 90-days post-LTx was 100% in both cohorts.

Acute rejection
In the first post-LTx year, at least 1 episode of biopsy proven acute cellular rejection (ACR) of any grade was identified in 47.3% of the allo-HSCT cohort compared to 65.8% of controls (p = 0.253). During this period, 31.6% of the allo-HSCT cohort were treated for ACR compared to 52.6% of controls (p = 0.165) (Table 3). At 1-year post-LTx, 80% of the allo-HSCT cohort had remained

Table 3 Post-lung transplant outcomes

|                                | Allo-HSCT cohort (n = 19) | Matched controls (n = 38) | p value |
|--------------------------------|---------------------------|---------------------------|---------|
| ICU length of stay (LOS), days | Median [IQR]              |                           |         |
| Post-LTx hospital LOS, days    | Median [IQR]              |                           |         |
| Biopsy proven acute cellular rejection | Any ACR grade |                           |         |
|                                | ACR > A1B0                |                           |         |
|                                | ACR treatment in the 1st post-LTx year | 31.6% (6) | 52.6% (20) | 0.165 |
| Antibody mediated rejection    | Presence of dnDSA2        | 20% (4 of 15)             | 59% (22 of 37) | 0.041 |
|                                | Time to DSA               | 73.5 days                 | 87.0 days | 0.777 |
|                                | Treatment for AMR         | 0%                        | 21.1% (8) | 0.042 |
| CMV viraemia                   | CMV D+/-R- match          | 100% (3)                  | 75% (6) | > 0.99 |
|                                | CMV D+/- or D+/-/R+ match | 30% (3)                   | 27.8% (5) |         |
| BAL microbiology3              | Category 1 pathogens      | 63.2% (12)                | 76.3% (29) | 0.356 |
|                                | Category 2 pathogens      | 57.9% (11)                | 36.8% (14) | 0.163 |
|                                | Category 1 or 2           | 79.0% (15)                | 76.3% (29) | > 0.99 |
|                                | Severe infections4        | 68.4% (13)                | 55.3% (21) | 0.401 |
|                                | Incidence of severe infections | 0.67 severe infections per patient per year | 0.36 severe infections per patient per year | 0.0705 |
| Chronic rejection              | CLAD-free at 3 years      | 78.0%                     | 74.9% | 0.721 |
|                                | Median time to CLAD       | 4.98 years                | Undefined | 0.622 |
| Graft survival                 | 1-year survival           | 100%                      | 97.1% | 0.473 |
|                                | 5-year survival           | 50.0%                     | 68.5% | 0.161 |
|                                | 10-year survival          | 25.0%                     | 56.1% | 0.059 |
| CLAD-free survival             | 3-year CLAD free survival | 52.1%                     | 71.1% | 0.306 |
|                                | Median CLAD free survival | 4.26 years                | Undefined | 0.142 |
|                                | Re-Transplant             | 0%                        | 7.9% (3) | 0.544 |

1 TBBx performed within the first 12 months following lung transplant
2 Presence of dnDSA during the 1st year post LTx
3 BAL performed in the 1st 24 months following LTx. Category 1 and 2 pathogens classified as clinically significant and usually clinically significant, respectively
4 Requiring in-patient admission or home IV treatment arranged. Excluded from this analysis were peri-operative infections (i.e., occurring during admission following transplant surgery) and infections that were managed as an out-patient with PO medication alone (e.g., CMV viraemia, NTM and Aspergillosis)
5 This p value was derived from comparing hazard ratio with the Andersen-Grill model
free from dnDSA, compared to 41% of the controls (p = 0.041, Table 3). Overall, the allo-HSCT cohort experienced greater freedom from dnDSA (p = 0.045; Fig. 1). No patient in the allo-HSCT cohort received treatment for antibody mediated rejection (AMR), compared with 21.1% in the control cohort (p = 0.042; Table 3).

Infection
Based on pre-LTx microbiology history, there was no statistical difference in the proportion of patients with a history of respiratory colonisation or infection due to Aspergillus species, Pseudomonas Aeruginosa or non-tuberculous mycobacteria. Airway flora at the time of LTx, assessed by recipient BAL, showed no difference in the proportion of patients colonised with category 1 (26.3% vs. 36.8%; p = 0.555) or category 2 (5.3% vs. 18.4%; p = 0.247) pathogens (Table 2).

In the 2 years following LTx (excluding peri-operative BAL results), there was no significant difference in the proportion of patients with at least one BAL culture that was positive for category 1 (63.2% vs. 76.3%; p = 0.356) or category 2 (57.9% vs. 36.8%; p = 0.163) pathogens (Table 3). Of the category 2 pathogen results, 52.6% of the allo-HSCT cohort culturing either Aspergillus Fumigatus or Mycobacterium Avium, compared to 29.0% of the matched cohort (p = 0.092).

Viral respiratory infections were identified (BAL or nasopharyngeal swab assessment) in 4 of the allo-HSCT cohort and 7 of the control cohort during follow up (21.1% vs. 18.4%; p > 0.999). This included 5 separate infections in the allo-HSCT cohort (Influenza × 3, RSV × 1, Coronavirus × 1) and 8 separate infections in the control (RSV × 5, Influenza × 3). RSV was managed as an inpatient with 5 days of inhaled ribavirin. Influenza cases were managed with oral oseltamivir as an outpatient.

The allo-HSCT cohort experienced 0.67 severe infections per year following LTx, classified as requiring either IV therapy or hospital admission (compared to 0.36 infections/patient/year in the control cohort). This corresponded to a hazard ratio for severe infection of 1.79 (95% CI 0.95–3.35; p = 0.07). CMV viraemia occurred in a similar proportion of patients in each cohort (Table 3). However, each LTx recipients with a primary CMV mismatch in the allo-HSCT cohort (CMV IgG D+/R-) required at least 1 admission for IV Ganciclovir (five episodes in three patients), with CMV disease being the cause of death in 1 case. In the matched cohort, CMV viraemia occurred in 6 of 8 CMV D+/R- LTx recipients, but only one required inpatient therapy (1 episode in 8 patients) and this was not associated with death. To assess the risk of severe CMV infections (i.e., requiring IV therapy) in LTx recipients with a primary CMV mismatch, we used a generalized estimating equations model adjusted for time to infection. The odds ratio for severe CMV infection was 8.94 with allo-HSCT (p = 0.056). Infection was the cause of death of 5 LTx recipients in the allo-HSCT cohort (CMV disease × 1, pneumonia × 2 and GI infection × 2) compared to 1 LTx recipient (bacteraemia × 1) in the propensity-score matched cohort. Using Gray’s K sample test, to compare the cumulative incidence of competing risk, there was an increased risk of death due to infection in the allo-HSCT cohort (Fig. 3a; p = 0.003).

Chronic rejection, hematologic relapse and post-LTx survival
There was no statistically significant difference in overall graft survival (Fig. 2; p = 0.059) or time to CLAD onset (Fig. 3c; p = 0.622) between the allo-HSCT cohort to the propensity-score matched cohort. However, in analysis conditional on 1-year survival, graft survival was reduced in the allo-HSCT cohort (Fig. 3b; p = 0.034), equating to a hazard ratio for death of 3.04 (1.09–8.49). Within the allo-HSCT cohort, there was no significant difference in post-LTx survival based on pre-LTx diagnosis (p = 0.368), pre-lung transplant treatment for GVHD (prednisone vs. prednisone + other immunosuppression; p = 0.221), time from allo-HSCT to LONIPC (< 5 years vs. ≥ 5 years; p = 0.348), or explant pathology (obliterative bronchiolitis vs. PPFE; p = 0.160).

CLAD was the cause of graft failure or death in 4 (21.1%) of the allo-HSCT cohort and 9 (23.78%) of the matched cohort (p > 0.999). Three patients in the matched cohort underwent re-LTx for CLAD (Table 3). One patient developed a relapse of their underlying hematologic malignancy (CML) post-LTx that was managed with imatinib and is currently in complete molecular remission.

![Figure 1: Freedom from de novo DSA following DLTx for LONIPCs of allo-HSCT compared to propensity-score matched controls](image-url)
Comparison to patients undergoing DLTx for CLAD
The observations that antibody-mediated rejection was less frequent, and infection was more frequent or severe, suggested a higher degree of immunosuppression in patients with allo-HSCT compared to propensity-matched LTx controls. Since patients requiring a re-transplant (re-LTx) for CLAD have a history of chronic immunosuppression, we elected to compare outcomes of patients undergoing a first re-LTx (DLTx only; n = 70; Additional file 1: Table S4) to that of the allo-HSCT cohort, within the same study period. Biopsy proven ACR (TBBx > A1B0) was identified in 10% of the re-LTx cohort, compared to 21.1% in the allo-HSCT cohort (p = 0.239). Overall post-LTx graft survival was similar (Fig. 4; p = 0.805) between cohorts, but there was a time-dependent mortality risk that differed between each cohort. The CLAD cohort had a higher risk of death during the early post-LTx phase (100% vs. 78.6% 1-year survival; p = 0.034). However, in patients surviving 1-year post-LTx, the allo-HSCT cohort experienced a hazard ratio of 1.99 for death (95% CI 0.79–5.01; p = 0.145) and 1.59 for infection-related death (95% CI 0.43–5.95; p = 0.489).

Discussion
In this study, we report that patients who undergo LTx for LONIPCs of allo-HSCT have an estimated 5-year survival of 50%. This compares favourably to the reported outcomes of patients who develop LONIPCs but do not
undergo LTx [5, 14]. However, in analysis conditional on 1-year survival, the allo-HSCT cohort experienced an increased mortality risk compared to propensity-score matched controls. The time to CLAD onset was similar in each cohort, but the allo-HSCT cohort experienced an increased risk of death due to infection. These results, added to lower rates of AMR, suggest that allo-HSCT LTx recipients experience a relatively increased state of immunosuppression compared to other LTx recipients.

Comparing outcomes of LTx for LONIPCs of allo-HSCT to outcomes of re-LTx for CLAD (within the same era), survival during the first post-LTx year was similar. However, following this 1st post-LTx year, there was a non-significant trend towards infection related deaths in the allo-HSCT cohort that we hypothesise may be the result of acquired immunodeficiencies related to allo-HSCT and not present in the re-LTx cohort.

Infectious complications occurring after allo-HSCT have previously been well described, with CMV infection and invasive aspergillosis being noteworthy [15–17]. The potential for serious infection in LTx recipients with a history of allo-HSCT has also been reported [18–20]. In the largest study of LTx for this indication, infection accounted for 41% of deaths during follow-up [21]. The authors identified the timing of allo-HSCT (within 2 years) and bridging to LTx (mechanical ventilation or ECLS) as risk factors for early sepsis related-mortality [21]. In our study, 26.5% of patients were bridged to LTx and 2 patients underwent LTx within 2 years of allo-HSCT, however survival to 1-year was 100%. Whether the improvement in early outcomes seen in this study is due to lack of statistical power or driven by differences in peri-operative immunosuppressive or anti-microbial therapy is an important question that should be answered by a prospective trial.

In attempting to explain the increased infection related mortality seen in this study, we hypothesise that acquired immunodeficiencies related to allo-HSCT alter the risk profile of these patients. We further hypothesise that the persistence of these acquired immunodeficiencies is the result of impaired or delayed immune reconstitution following allo-HSCT. Whilst functional innate immunity is generally thought to recover within a few months of allo-HSCT, a significant proportion of patients experience adaptive immune deficits at 1-year [22] and ongoing immunological deficits present at greater than 10 years have been reported [23]. Unfortunately, detailed assessment of the pathways underpinning prolonged immunodeficiency are lacking, although T- and B- cell memory responses, T-cell diversity and regulatory T-cell balance have been implicated [24]. This immunological dysfunction is likely further exacerbated by chronic GVHD [25], which may further delay T-cell immune reconstitution [26] and potentiate B-cell deficiency [27]. It is notable that all patients in this study experienced chronic GVHD affecting at least 1 organ at the time of LTx.

The optimal approach for translating knowledge regarding potential immunodeficiency and resultant infection risk into post-LTx management is not clear cut. It might be argued that a less intensive immunosuppressive regimen should be provided to LTx recipients with previous allo-HSCT. However, the complexity of the pathobiology and the impact of individualised factors in the pathogenesis of these deficits, makes a “one-size-fits-all” strategy inappropriate for this cohort. Our study suggests that these patients commonly experience humoral immune deficiencies, evidenced by the high proportion of patients receiving immunoglobulin replacement and the low rates of DSA development post-LTx. However, T-cell mediated rejection (ACR) remains an ongoing concern, with 31.6% of the allo-HSCT cohort requiring treatment for this during the first post-LTx year—similar to ACR rates reported by international registries (for all LTx recipients) [28]. Furthermore, when compared to re-LTx for CLAD, a greater proportion of the allo-HSCT cohort developed mild-moderate ACR (21.1% vs. 10.0%; p = 0.239).

Balancing the impact of acquired immunodeficiencies on graft function, infection and rejection in this situation is therefore quite complex. We would consider the most prudent approach to be careful assessment of the degree of impairment of host immunity prior to LTx, followed by a personalised immunosuppression strategy post-LTx with careful monitoring. In moving the field towards precision medicine, the development of assays that allow for personalised immunosuppressive approaches remains a key research priority [29]—as highlighted by this study. However, while we wait for this breakthrough, strategies...
to optimise post-LTx outcomes in allo-HSCT recipients might include prolonged CMV prophylaxis [30], pre-emptive anti-microbial therapy [31], monitoring for immunoglobulin deficiency, and in appropriate cases, careful reduction of maintenance immunosuppression (compared to standard regimens).

The conclusions drawn from this study are limited by retrospective design, sample size and inclusion period. However, this study adds to the limited evidence base regarding post-LTx outcomes for this rare indication. Furthermore, ongoing increases in allo-HSCT activity may lead to LONIPCs becoming a more frequent indication for LTx in the future. As such, improving our understanding of potentially modifiable risk factors is important if outcomes are to improve. To summarise, LTx is a feasible option for patients with LONIPCs of allo-HSCT but post-LTx infectious complications are a concern and evidence-based strategies to reduce this risk are required.

Abbreviations
ACR: Acute cellular rejection; allo-HSCT: Allogeneic hematopoietic stem cell transplantation; CMX: Antibody cross match; AMR: Antibody mediated rejection; ATG: Anti-thymocyte globulin; BAL: Bronchoalveolar lavage; cGVHD: Chronic graft-versus-host disease; CLAD: Chronic lung allograft dysfunction; CML: Chronic myeloid leukaemia; CMV: Cytomegalovirus; DLTx: Double lung transplantation; DSA: Donor specific antibody; EVLP: Ex vivo lung perfusion; ECLS: Extracorporeal life support; LONIPCs: Late-onset non-infectious pulmonary complications; LOS: Length of stay; LTx: Lung transplantation; PCR: Polymerase-chain reaction; re-LTx: Re-transplantation; TBI: Total body irradiation; TBBx: Transbronchial lung biopsy.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-021-01699-8.

Additional file 1: Table S1. Classification of BAL pathogens. Table S2. Classification of waiting list status. Table S3. Lung donor characteristics. Table S4. Recipient characteristics at the time of re-transplant for chronic lung allograft dysfunction.

Acknowledgements
The authors would like to thank Dr T Martinu and Mr R Ghany for their assistance with retrieval of data from the Toronto lung transplant database.

Authors’ contributions
PR, RV-N, SCJ: Participated in research design; Participated in the writing of the paper; Participated in the performance of the research; Participated in data analysis. JM, LGS, JHL: Participated in research design; Participated in the writing of the paper; Participated in data analysis. All authors read and approved the final manuscript.

Funding
This work was supported by funds from the Toronto General Hospital Foundation. This funding body had no role in: The design of the study; The collection, analysis, or interpretation of data; The writing of the manuscript.

Availability of data and materials
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was performed with approval of the institutional review board at the University Health Network, Toronto.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Ajmera Transplant Centre and Toronto Lung Transplant Program, Toronto General Hospital, Toronto, Canada. 2 Hans Messner Allogenic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada. 3 Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, Canada.

Received: 29 January 2021 Accepted: 29 March 2021 Published online: 07 April 2021

References
1. Bergeron A, Chevet S, Peffault de Latour R, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J 2018; 51(5).
2. Gazoulian L, Spring L, Meserve E, et al. Pulmonary clinicopathological correlation after allogeneic hematopoietic stem cell transplantation: an autopsy series. Biol Blood Marrow Transplant. 2017;23(10):1767–72.
3. Higo H, Miyahara N, Taniguchi A, Maeda Y, Kura K. Cause of pneumo‑parenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. Respir Investig. 2019;57(4):321–4.
4. Bergeron A. Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Clin Chest Med. 2017;38(2):249–62.
5. Ueda K, Watadani T, Maeda E, et al. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1719–27.
6. Nakaseko C, Ozawa S, Sakaida E, et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93(3):375–82.
7. Ditschkowski M, Elmaagacli AH, Koldenhoff M, Gronike T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transplant. 2013;48(9):1224–9.
8. Bondeelle L, Bergeron A. Managing pulmonary complications in allo‑HSCT recipients with perioperative desensitization. Expert Rev Respir Med. 2015;15(2):417–26.
9. Weill D, Bendon C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15.
10. Tinkamk KJ, Keshavjee S, Chaparro C, et al. Survival in sensitized lung transplant recipients with perioperative desensitization. Am J Transplant. 2015;15(2):417–26.
11. Levy L, Huszti E, Tikkanen J, et al. The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation. Am J Transplant. 2020;20(1):241–9.
12. Hansen BB, Kloper SO. Optimal full matching and related designs via network flows. J Comput Graph Stat. 2006;15(3):609–27.
13. Wait list, organ offers and allocation policies. 2019. https://www.giftsoflight.ca/resources/pdf/healthcare/TP_9_100_Dec1719.pdf.
14. Baird K, Steinberg SM, Grkovic L, et al. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplantation. J Am Soc Blood Marrow Transplantation. 2013;19(4):632–9.
15. Montoro J, Piñana JL, Hernández-Boluda JC, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant. 2020.

16. Jin H, Fan Z, Huang F, et al. Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study. Infection. 2019;47(2):273–84.

17. Yong MK, Ananda-Rajah M, Cameron PU, et al. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant. 2017;23(11):1961–7.

18. Cheng GS, Edelman JD, Maddes DK, Martin PJ, Flowers ME. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1169–75.

19. Vogl UM, Nagayama K, Bögic M, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation. 2013;95(4):623–8.

20. Kliman DS, Kotecha SR, Abelosn DC, Snell GI, Glanville AR, Ma DDF. Favorable outcome of lung transplantation for severe pulmonary graft versus host disease: an Australian multicenter case series. Transplantation. 2019;103(2):2602–7.

21. Greer M, Berastegui C, Jaksch P, et al. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience. Eur Respir J 2018;51(2).

22. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115(3):630–41.

23. Battinwalla M, Tichelli A, Majhail NS. Long-term survivorship after hematopoietic cell transplantation: roadmap for research and care. Biol Blood Marrow Transplant. 2017;23(2):184–92.

24. Gea-Banacloche J, Komanduri KV, Carpenter P, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the immune dysregulation and pathobiology working group report. Biol Blood Marrow Transplant. 2017;23(6):870–81.

25. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–84.

26. Fujimaki K, Maruta A, Yoshida M, et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;27(12):1275–81.

27. Corre E, Carmagnat M, Bussin M, et al. Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica. 2010;95(6):1025–9.

28. International Thoracic Organ Transplant (ITX) Registry Data Slides 2019. https://ishltregistries.org/registries/slides.asp.

29. Juvet SC, Sanderson S, Hester J, Wood KJ, Bushell A. Quantification of CD4(+) T cell alloreactivity and its control by regulatory T cells using time-lapse microscopy and immune synapse detection. Am J Transplant. 2016;16(5):1394–407.

30. Casola S, Khan B, Singer LG, et al. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: a retrospective study. Transpl Infect Dis 2020: e13277.

31. Husain S, Bhaskaran A, Rotstein C, et al. A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transplant. 2018;37(7):886–94.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more: biomedcentral.com/submissions

At BMC, research is always in progress.